Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response.

Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print Cited Medium: Internet ISSN: 1365-2567 (Electronic) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE

Original Publication: Oxford : Blackwell Scientific Publications

Interferon Type I/*immunology ; Interferon Type I/*metabolism ; Interferon-gamma/*immunology ; Interferon-gamma/*metabolism ; Receptor, Interferon alpha-beta/*metabolism; Animals ; Ligands ; Mice ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Knockout ; Receptor, Interferon alpha-beta/deficiency ; Receptor, Interferon alpha-beta/immunology

Separate ligand-receptor paradigms are commonly used for each type of interferon (IFN). However, accumulating evidence suggests that type I and type II IFNs may not be restricted to independent pathways. Using different cell types deficient in IFNAR1, IFNAR2, IFNGR1, IFNGR2 and IFN-γ, we evaluated the contribution of each element of the IFN system to the activity of type I and type II IFNs. We show that deficiency in IFNAR1 or IFNAR2 is associated with impairment of type II IFN activity. This impairment, presumably resulting from the disruption of the ligand-receptor complex, is obtained in all cell types tested. However, deficiency of IFNGR1, IFNGR2 or IFN-γ was associated with an impairment of type I IFN activity in spleen cells only, correlating with the constitutive expression of type II IFN (IFN-γ) observed on those cells. Therefore, in vitro the constitutive expression of both the receptors and the ligands of type I or type II IFN is critical for the enhancement of the IFN activity. Any IFN deficiency can totally or partially impair IFN activity, suggesting the importance of type I and type II IFN interactions. Taken together, our results suggest that type I and type II IFNs may regulate biological activities through distinct as well as common IFN receptor complexes.
(© 2014 John Wiley & Sons Ltd.)

J Immunol. 2007 Jun 15;178(12):7540-9. (PMID: 17548588)
J Mol Biol. 1999 Nov 19;294(1):223-37. (PMID: 10556041)
Curr Opin Biotechnol. 1991 Dec;2(6):847-50. (PMID: 1367959)
J Virol. 1981 Feb;37(2):755-8. (PMID: 6163873)
J Immunol. 2005 Jan 15;174(2):609-13. (PMID: 15634877)
Immunol Res. 2005;32(1-3):231-45. (PMID: 16106075)
Oncologist. 2001;6(1):34-55. (PMID: 11161227)
J Immunol. 1996 Sep 1;157(5):1935-43. (PMID: 8757312)
J Immunol. 2000 Jan 1;164(1):201-7. (PMID: 10605012)
Curr Opin Virol. 2011 Dec;1(6):476-86. (PMID: 22323926)
Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-18-S9-40. (PMID: 9208871)
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):473-82. (PMID: 17693124)
Science. 2011 Mar 25;331(6024):1565-70. (PMID: 21436444)
J Immunol. 1997 Jul 1;159(1):206-13. (PMID: 9200456)
Annu Rev Biochem. 1998;67:227-64. (PMID: 9759489)
Immunol Rev. 2012 Nov;250(1):317-34. (PMID: 23046138)
Methods Enzymol. 1981;78(Pt A):387-94. (PMID: 6173617)
Clin Dev Immunol. 2011;2011:349575. (PMID: 22190970)
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8737-41. (PMID: 8378357)
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8233-8. (PMID: 9653170)
J Biol Chem. 2011 Sep 2;286(35):30888-30897. (PMID: 21730069)
J Exp Med. 2011 Sep 26;208(10):1989-2003. (PMID: 21930769)
Cell. 1996 Feb 9;84(3):443-50. (PMID: 8608598)
J Biol Chem. 2007 Jul 13;282(28):20053-7. (PMID: 17502368)
Virulence. 2010 Sep-Oct;1(5):418-22. (PMID: 21178482)
Eur J Immunol. 1993 Jun;23(6):1226-31. (PMID: 8500521)
J Leukoc Biol. 2006 Jun;79(6):1286-94. (PMID: 16624932)
J Immunol. 2011 Sep 1;187(5):2578-85. (PMID: 21810606)
Curr Biol. 1998 Feb 12;8(4):223-6. (PMID: 9501984)
Nat Immunol. 2005 Jul;6(7):722-9. (PMID: 15951814)
EMBO J. 1993 Nov;12(11):4221-8. (PMID: 7693454)
Cancer Res. 2006 Apr 15;66(8):4468-77. (PMID: 16618774)
Immunol Rev. 2004 Dec;202:8-32. (PMID: 15546383)
J Leukoc Biol. 2001 Dec;70(6):950-60. (PMID: 11739558)
Annu Rev Immunol. 2009;27:591-619. (PMID: 19132916)
Cytokine Growth Factor Rev. 1997 Sep;8(3):189-206. (PMID: 9462485)
Pharmacol Ther. 2005 Jun;106(3):299-346. (PMID: 15922016)
J Biol Chem. 2006 May 19;281(20):14111-8. (PMID: 16571725)
J Mol Biol. 2007 Feb 16;366(2):525-39. (PMID: 17174979)
Immunity. 2012 Feb 24;36(2):166-74. (PMID: 22365663)
Bioessays. 2001 Feb;23(2):161-9. (PMID: 11169589)
J Virol. 1999 Jun;73(6):5196-200. (PMID: 10233988)
J Exp Med. 1994 Apr 1;179(4):1367-71. (PMID: 7908325)
J Interferon Cytokine Res. 2005 Dec;25(12):780-7. (PMID: 16375606)
Biochimie. 1998 Aug-Sep;80(8-9):779-88. (PMID: 9865499)
Oncogene. 2000 May 15;19(21):2468-73. (PMID: 10851045)
Nat Rev Immunol. 2005 May;5(5):375-86. (PMID: 15864272)
Science. 1994 Jun 24;264(5167):1918-21. (PMID: 8009221)
Nat Immunol. 2003 Jan;4(1):63-8. (PMID: 12469119)
PLoS Biol. 2010 Apr 27;8(4):e1000361. (PMID: 20436908)
J Exp Med. 1995 Mar 1;181(3):961-71. (PMID: 7869054)
Cell Res. 2006 Jan;16(1):55-69. (PMID: 16467876)
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205. (PMID: 8108387)
Cell. 1994 Mar 11;76(5):793-802. (PMID: 8124716)
Science. 2000 Jun 30;288(5475):2357-60. (PMID: 10875919)
Nat Immunol. 2003 Jan;4(1):69-77. (PMID: 12483210)
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11917-22. (PMID: 16081539)
Semin Oncol. 2002 Jun;29(3 Suppl 7):18-26. (PMID: 12068384)
Curr Opin Immunol. 2011 Oct;23(5):583-90. (PMID: 21840693)
J Biol Chem. 2000 Dec 22;275(51):40425-33. (PMID: 10984492)

R01 CA132624 United States CA NCI NIH HHS; CA132624 United States CA NCI NIH HHS; AR055073 United States AR NIAMS NIH HHS; P30 CA072720 United States CA NCI NIH HHS; P30 ES005022 United States ES NIEHS NIH HHS; R01 051139 United States PHS HHS; U54 AR055073 United States AR NIAMS NIH HHS; ES005022 United States ES NIEHS NIH HHS; ES004738 United States ES NIEHS NIH HHS; R01 ES004738 United States ES NIEHS NIH HHS

Keywords: T cells; cell types; constitutive interferon; interferon receptor paradigm; interferon response; type I and type II interferon receptors

0 (Ifnar1 protein, mouse)
0 (Ifnar2 protein, mouse)
0 (Interferon Type I)
0 (Ligands)
156986-95-7 (Receptor, Interferon alpha-beta)
82115-62-6 (Interferon-gamma)

Date Created: 20140307 Date Completed: 20140928 Latest Revision: 20240109

20250114

PMC4080960

10.1111/imm.12273

24597649